Aspirin: benefit and risk in thromboprophylaxis.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  QJM : monthly journal of the Association of Physicians

• Publication date

  1998-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/QJMED/91.8.523PMID 9893756
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The effects of different doses of some acetylsalicylic acid formulations on platelet function and bleeding times in healthy subjects.

  2009cited by this paper
• The bleeding time: current practice in the UK.

  2008cited by this paper
• Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function

  2004cited by this paper
• [Prevention of stroke].

  1999cited by this paper
• CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.

  1997cited by this paper
• The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group.

  1997cited by this paper
• Bleeding Classification in Clinical Trials: Observer Variability and Clinical Relevance

  1997cited by this paper
• Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis

  1996cited by this paper
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

  1996cited by this paper
• Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product.

  1996cited by this paper
• Unplanned reoperation for bleeding.

  1996cited by this paper
• European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.

  1996cited by this paper
• Complications of cutaneous surgery in patients who are taking warfarin, aspirin, or nonsteroidal anti-inflammatory drugs.

  1996cited by this paper
• Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses.

  1995cited by this paper
• Pilot trial of the effects of low-dose acetylsalicylic acid on platelet thromboxane B2 production.

  1995cited by this paper
• Toxicity of nonsteroidal anti-inflammatory drugs in the large intestine

  1995cited by this paper
• Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin--analysis of gastrointestinal bleeding during the UK-TIA trial.

  1995cited by this paper
• Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically.

  1995cited by this paper
• Pre-operative aspirin decreases platelet aggregation and increases post-operative blood loss--a prospective, randomised, placebo controlled, double-blind clinical trial in 100 patients with chronic stable angina.

  1994cited by this paper
• Anti-inflammatory analgesics and drugs used in gout

  1994cited by this paper
• Use of desmopressin acetate to reduce blood transfusion requirements during cardiac surgery in patients with acetylsalicylic-acid-induced platelet dysfunction.

  1994cited by this paper
• Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group.

  1994cited by this paper
• Safety and anticoagulation effect of a low-dose combination of warfarin and aspirin in clinically stable coronary artery disease. Coumadin Aspirin Reinfarction (CARS) Pilot Study Group.

  1994cited by this paper
• Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

  1994cited by this paper
• Acetylsalicylic acid in the prevention of early stenosis and occlusion of transjugular intrahepatic portal‐systemic stent shunts: A controlled study

  1994cited by this paper
• Use of desmopressin (DDAVP) in controlling aspirin-induced coagulopathy after cardiac surgery.

  1994cited by this paper
• Antiplatelet therapy to prevent thrombosis after hip fracture. Rationale for a randomised trial.

  1994cited by this paper
• CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group.

  1994cited by this paper
• Aspirin does not increase homologous blood requirements in elective coronary bypass surgery.

  1994cited by this paper
• Review article: aspirin and gastrointestinal bleeding

  1994cited by this paper
• Aprotinin preserves hemostasis in aspirin-treated patients undergoing cardiopulmonary bypass.

  1994cited by this paper
• Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients.

  1993cited by this paper
• Prevention of one-year vein-graft occlusion after aortocoronary-bypass surgery: a comparison of low-dose aspirin, low-dose aspirin plus dipyridamole, and oral anticoagulants. The CABADAS Research Group of the Interuniversity Cardiology Institute of The Netherlands.

  1993cited by this paper
• The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials.

  1993cited by this paper
• Prevention of preeclampsia with low‐dose aspirin in healthy, nulliparous pregnant women

  1993cited by this paper
• Rapid and selective inhibition of platelet aggregation and thromboxane formation by intravenous low dose aspirin in man.

  1993cited by this paper
• The use of proprietary medicines by patients presenting with peptic ulcer haemorrhage.

  1993cited by this paper
• A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement.

  1993cited by this paper
• Expression of mRNA for cyclooxygenase‐1 and cyclooxygenase‐2 in human tissues

  1993cited by this paper
• Adverse effects of low‐dose aspirin in a healthy elderly population

  1993cited by this paper
• The effect of regular and enteric-coated aspirin on bleeding time, thromboxane, and prostacyclin.

  1993cited by this paper
• Anticoagulants, antiaggregants or nothing following carotid endarterectomy?

  1993cited by this paper
• Aprotinin reduces cardiopulmonary bypass‐induced blood loss and inhibits fibrinolysis without influencing platelets

  1993cited by this paper
• Easy bruisability, aspirin intolerance, and response to DDAVP®

  1993cited by this paper
• Dose‐Dependent Aspirin Hydrolysis and Platelet Aggregation in Patients with Atherosclerosis

  1992cited by this paper
• Efficacy and safety of anticoagulant therapy started pre-operatively in preventing coronary vein graft occlusion.

  1992cited by this paper
• Extra-Cranial Bleeding and Other Symptoms due to Low Dose Aspirin and Low Intensity Oral Anticoagulation

  1992cited by this paper
• Gastric changes in coronary-operated patients with low-dose aspirin.

  1992cited by this paper
• The effect of desmopressin acetate on postoperative hemorrhage in patients receiving aspirin therapy before coronary artery bypass operations.

  1992cited by this paper
• Preoperative aspirin therapy and reoperation for bleeding after coronary artery bypass surgery.

  1991cited by this paper
• Separation of the impairment of haemostasis by aspirin from mucosal injury in the human stomach.

  1991cited by this paper
• Immediate Postoperative Aspirin Improves Vein Graft Patency Early and Late After Coronary Artery Bypass Graft Surgery: A Placebo‐Controlled, Randomized Study

  1991cited by this paper
• Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin.

  1991cited by this paper
• Antiplatelet drugs in femoropopliteal vein bypasses: a multicenter trial.

  1991cited by this paper
• A comparison of template bleeding time with mucosal petechiometry as a measure of the platelet function defect induced by aspirin.

  1991cited by this paper
• The clinical importance of acquired abnormalities of platelet function.

  1991cited by this paper
• Non-steroidal anti-inflammatory drugs and peptic ulcers.

  1990cited by this paper
• The bleeding time response to aspirin. Identifying the hyperresponder.

  1990cited by this paper
• A Critical Reappraisal of the Bleeding Time*

  1990cited by this paper
• Effect of dipyridamole and aspirin on vein graft patency after coronary bypass operations.

  1990cited by this paper
• Does Preoperative Antiplatelet Therapy Increase the Risk of Hemorrhagic Complications Associated With Regional Anesthesia?

  1990cited by this paper
• Coagulation, Fibrinolytic and Platelet Function in Patients on Long-Term Therapy with Aspirin 300 mg or 1200 mg Daily Compared with Placebo

  1990cited by this paper
• Response of thromboxane B2, malondialdehyde and platelet sensitivity to 3 weeks low-dose aspirin (ASA) in healthy volunteers.

  1989cited by this paper
• Final report on the aspirin component of the ongoing Physicians' Health Study.

  1989cited by this paper
• Differential inhibition by aspirin of platelet thromboxane and renal prostaglandins in the rat.

  1989cited by this paper
• Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator.

  1989cited by this paper
• Post-tonsillectomy haemorrhage and analgesics. A comparative study of acetylsalicylic acid and paracetamol.

  1988cited by this paper
• A study of bleeding time in 120 long-term aspirin trial patients.

  1988cited by this paper
• Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting.

  1988cited by this paper
• Differential effects of oral administrations to human volunteers of acetylsalicylic acid, sodium salicylate and indomethacin on 12-hydroxyeicosatetraenoic acid formation by stimulated platelets.

  1988cited by this paper
• Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study.

  1988cited by this paper
• Aspirin dose, bleeding time, platelet adhesion and aggregation in cerebral thrombosis.

  1988cited by this paper
• Aspirin, heparin, or both to treat acute unstable angina.

  1988cited by this paper
• Effect of aspirin plus hydrochloric acid on the gastric mucosal microcirculation.

  1987cited by this paper
• Significance of occult gastrointestinal bleeding during anticoagulation therapy.

  1987cited by this paper
• Inhibition of prostacyclin and thromboxane A2 generation by low-dose aspirin at the site of plug formation in man in vivo.

  1987cited by this paper
• Template bleeding time after ingestion of ultra low dosages of acetyl salicylic acid in healthy subjects. Preliminary study.

  1987cited by this paper
• Effects of low doses of aspirin, 10 mg and 30 mg daily, on bleeding time, thromboxane production and 6-keto-PGF1 alpha excretion in healthy subjects.

  1987cited by this paper
• Does sucralfate reduce acetylsalicylic-acid-induced gastric mucosal bleeding?

  1987cited by this paper
• Alterations in blood vessels during gastric injury and protection.

  1986cited by this paper
• Aspirin inhibits platelet 12-hydroxy-eicosatetraenoic acid formation.

  1986cited by this paper
• Relationship between structure and activity of aspirin-related compounds on the inhibition of in vitro platelet aggregation.

  1986cited by this paper
• Hemostatic mechanisms, independent of platelet aggregation, arrest gastric mucosal bleeding.

  1986cited by this paper
• Platelet aggregation and thromboxane release induced by arachidonic acid, collagen, ADP and platelet-activating factor following low dose acetylsalicylic acid in man.

  1986cited by this paper
• Pharmacology of platelet inhibition in humans: implications of the salicylate-aspirin interaction.

  1985cited by this paper
• Prostaglandins and the gastrointestinal mucosa: are they important in its function, disease, or treatment?

  1985cited by this paper
• Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole.

  1983cited by this paper
• Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs.

  1983cited by this paper
• Models for clinical assessment of oral analgesics.

  1983cited by this paper
• Low-dose aspirin inhibits platelet and venous cyclo-oxygenase in man.

  1982cited by this paper
• A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction.

  1982cited by this paper
• Prostaglandins: gastrointestinal effects and peptic ulcer disease.

  1981cited by this paper
• Salicylate-induced gastrointestinal bleeding: comparison between soluble buffered, enteric-coated, and intravenous administration.

  1979cited by this paper
• Inhibition of platelet prostaglandin synthetase by oral aspirin.

  1978cited by this paper
• Acetylsalicylic acid vs paracetamol: Effects on post-operative course

  1977cited by this paper
• Absorption kinetics of aspirin in man following oral administration of an aqueous solution.

  1972cited by this paper
• Aspirin-induced occult gastrointestinal blood loss. Local versus systemic effects.

  1970cited by this paper
• Failure of Intravenous Aspirin to Increase Gastrointestinal Blood Loss

  1969cited by this paper
• The standardized normal Ivy bleeding time and its prolongation by aspirin.

  1969cited by this paper
• Impaired platelet-connective-tissue reaction in man after aspirin ingestion.

  1967cited by this paper

• Incidence and Clinical Characteristics of Upper Gastrointestinal Bleeding in Patients with Antithrombotic Therapy

  2017cites this paper
• Low-dose acetylsalicylic acid use and the risk of upper gastrointestinal bleeding: a meta-analysis of randomized clinical trials and observational studies.

  2013cites this paper
• Magnetic Active Agent Release System (MAARS): evaluation of a new way for a reproducible, externally controlled drug release into the small intestine.

  2012cites this paper
• Does Low Dose Aspirin Increase Gastrointestinal Bleeding

  2012cites this paper
• Technology assessment report commissioned by the HTA Programme on behalf of The National Institute for Clinical Excellence

  2008cites this paper
• Aspirin and Cardiovascular Prevention in the Guidelines and in the Real World

  2005cites this paper
• Are evidence-based cardiovascular prevention therapies being used? A review of aspirin and statin therapies

  2005cites this paper
• Antiplatelet therapy and spontaneous perirenal hematoma

  2005cites this paper
• Aspirin Therapy for the Primary Prevention of Cardiovascular Disease

  2004cites this paper
• Acute Ischaemic Stroke: Management, Recent Advances and Controversies

  2004cites this paper
• Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation.

  2004cites this paper
• Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.

  2004cites this paper
• An update on 'progression promoters' in renal diseases.

  2003cites this paper
• Aspirin for the Primary Prevention of Cardiovascular Events: Recommendation and Rationale

  2002cites this paper
• Recommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs: defining the role of gastroprotective agents.

  2002cites this paper
• Aspirin for the primary prevention of cardiovascular events: recommendations and rationale.

  2002cites this paper
• Aspirin for the primary prevention of cardiovascular events: recommendations and rationale.

  2002cites this paper
• Aspirin for the Primary Prevention of Cardiovascular Events: A Summary of the Evidence for the U.S. Preventive Services Task Force

  2002cites this paper
• Aspirin intake and the use of serum ferritin as a measure of iron status.

  2001cites this paper
• NSAIDS and selective COX-2 inhibitors: competition between gastroprotection and cardioprotection.

  2001cites this paper
• Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies.

  2001cites this paper
• Renoprotection: one or many therapies?

  2001cites this paper
• Drugs used in secondary prevention after myocardial infarction: case presentation.

  2000cites this paper
• [Pharmacology of aspirin].

  2000cites this paper
• NSAIDs and Alcohol: Never the Twain Shall Mix?

  1999cites this paper